FIELD: medicine; cardiology; endocrinology.
SUBSTANCE: present group of inventions concerns prevention of severe adverse cardiovascular event. That is ensured by determining the level of hGH and/or its isoforms in a blood sample of said individual and comparing it with a predetermined threshold value. If the established level of hGH and/or isoform thereof exceeds said predetermined threshold level, the individual is identified as having a vascular risk, which can be reduced by antihypertensive drugs.
EFFECT: this provides stratification of patients for well-timed pharmacotherapy, which, in turn, enables preventing development of severe cardiovascular pathology.
23 cl, 12 tbl, 5 ex, 8 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| USING PCSK9 INHIBITOR FOR REDUCING CARDIOVASCULAR RISK | 2019 |
|
RU2837845C2 |
| RENIN-ANGIOTENSIN SYSTEM INHIBITORS APPLICATION FOR PREVENTING CARDIOVASCULAR DISEASE MANIFESTATIONS | 2000 |
|
RU2276997C2 |
| TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | 2004 |
|
RU2380093C2 |
| RENIN INHIBITOR-CONTAINING SYNERGETIC COMPOSITIONS DESIGNATED FOR TREATMENT OF CARDIOVASCULAR DISEASE | 2001 |
|
RU2310443C2 |
| SYNERGETIC COMBINATIONS CONTAINING RENIN INHIBITOR AND INTENDED FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2006 |
|
RU2346703C2 |
| METHOD OF TREATING CARDIOVASCULAR DISEASES | 2012 |
|
RU2570752C2 |
| METHODS FOR TREATMENT OF HYPERLIPIDEMIA IN PATIENTS WITH DIABETES BY INJECTION OF PCSK9 INHIBITOR | 2018 |
|
RU2772712C2 |
| METHOD DETERMINING TACTICS OF CARRYING OUT OF MEDICAL ACTIONS AT PATIENTS WITH METABOLIC SYNDROME AGAINST ARTERIAL HYPERTENSIA | 2007 |
|
RU2337612C1 |
| RISK MARKERS FOR CARDIOVASCULAR DISEASES IN PATIENTS WITH CHRONIC KIDNEY DISEASE | 2014 |
|
RU2656148C2 |
| COFORMULATED DRUG FOR CARDIOVASCULAR DISEASES BASED ON CHRONOTHERAPY THERAPY | 2007 |
|
RU2464014C2 |
